The DOI matches its Crossref record; 196 of the 206 references it cites were found in a registry or an index.
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods: MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results: 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 patients determined that the prevalence rates of NAFLD and NASH in T2DM were 65.04% (95% CI 61.79% to 68.15%, I 2 =99.90%) and 31.55% (95% CI 17.12% to 50.70%, I 2 =97.70%), respectively. 35.54% (95% CI 19.56% to 55.56%, I 2 =100.00%) of individuals with T2DM with NAFLD had clinically significant fibrosis (F2–F4), while 14.95% (95% CI 11.03% to 19.95%, I 2 =99.00%) had advanced fibrosis (F3–F4). Conclusion: This study determined a high prevalence of NAFLD, NASH and fibrosis in people with T2DM. Increased efforts are required to prevent T2DM to combat the rising burden of NAFLD. PROSPERO registration number: CRD42022360251.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The urgency for treatment is further heightened by its strong bidirectional association with type 2 diabetes (T2D)—each disease independently increases the risk of developing the other and exacerbates its severity.4,5”
In the citing paper
“but the risk is much higher in the presence of T2D (42-65% have steatosis). 15,16”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [16]
In the citing paper
“It has been estimated that approximately 10 -30% of persons with isolated steatosis progress to steatohepatitis and advanced liver disease”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [16]
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationThe prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Research works printed but not linked: 4
- Huang DQ , Wilson LA , Behling C , et al . Fibrosis progression rate in biopsy-proven Nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: A multicenter study. Gastroenterology 2023. doi:10.1053/j.gastro.2023.04.025 · DOI · Paper page
- 2015, Standards of medical care in Diabetes--2015: summary of revisions, Diabetes Care, 38 Suppl
- Muthiah, 2023, Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis, Ann Hepatol, 28, 100762, 10.1016/j.aohep.2022.100762 · DOI
- Ajmera V , Cepin S , Tesfai K , et al . 2023 A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. Journal of Hepatology:471–8. doi:10.1016/j.jhep.2022.11.010 Available: doi:https://doi.org/10.1016/j.jhep.2022.11.010 · DOI · Paper page
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Self-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.006 · Cited by 416
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Metadata
- Authors
- En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., Chee, D., Nah, B., Lesmana, C. R. A., Bwa, A. H., Win, K. M., Faulkner, C., Aboona, M. B., Lim, M. C., Syn, N., Kulkarni, A. V., Suzuki, H., Takahashi, H., Tamaki, N., Wijarnpreecha, K., Huang, D. Q., Muthiah, M., Ng, C. H., & Loomba, R.
- Affiliations
- Department of Medicine, National University Hospital, Singapore
- National University Hospital (SG)
- National University of Singapore (SG)
- University of Indonesia (ID)
- Department of Medical Research, Union of Myanmar, Naypyidaw, Myanmar
- University of Arizona College of Medicine- Phoenix (US)
- Asian Institute of Gastroenterology (IN)
- Kurume University (JP)
- Saga University (JP)
- University of California San Diego (US)
- University of Michigan (US)
- Corresponding author
- Ng, Cheng Han
- ORCID
- En Li Cho, Elina
- Quek, Jingxuan
- Fu, Clarissa Elysia
- Lim, Lincoln Kai En
- Tan, Darren Jun Hao
- Lim, Wen Hui
- Yong, Jie Ning
- Zeng, Rebecca
- Chee, Douglas
- Nah, Benjamin
- Lesmana, Cosmas Rinaldi Adithya
- Bwa, Aung Hlaing
- Win, Khin Maung
- Faulkner, Claire
- Aboona, Majd B
- Lim, Mei Chin
- Syn, Nicholas
- Kulkarni, Anand V.
- Suzuki, Hiroyuki
- Takahashi, Hirokazu
- Tamaki, Nobuharu
- Wijarnpreecha, Karn
- Huang, Daniel Q.
- Muthiah, Mark
- Ng, Cheng Han
- Loomba, Rohit
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2023-07-25
- Volume
- 72
- Issue
- 11
- Pages
- 2138-2148
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W4385237448
- Cited by
- 380
- References
- 206
- Citations by year
- 2026: 135 · 2025: 154 · 2024: 79 · 2023: 12
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, prevalence, nonalcoholic steatohepatitis, liver fibrosis, advanced fibrosis, insulin resistance, chronic inflammation
- MeSH terms
- Diabetes Mellitus, Type 2, Fibrosis, Humans, Insulin Resistance, Prevalence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/gutjnl-2023-330110
- The paper
- En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., Chee, D., Nah, B., Lesmana, C. R. A., Bwa, A. H., Win, K. M., Faulkner, C., Aboona, M. B., Lim, M. C., Syn, N., . . . Loomba, R. (2023). Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. https://doi.org/10.1136/gutjnl-2023-330110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.